Telios Pharmaceuticals Inc. said it has started clinical trials ofits TelioDerm wound healer in two additional applications, skingrafting in the elderly and for second-degree burns in children.
Trials of the San Diego company's peptide-based product arealready in progress for healing skin ulcers, including thoseassociated with venous stasis, diabetes and sickle cell disease.Telios (NASDAQ:TLIO) said it has begun analysis of the venousstasis trial data, with results expected by late in the year.
The stock lost 25 cents to $6.38.
(c) 1997 American Health Consultants. All rights reserved.